Business Context and Reporting Period
Heron Therapeutics, Inc. filed this unaudited Form 10-Q for the quarter ended March 31, 2017. Heron was transitioning to a commercial-stage biotechnology company following FDA approval of SUSTOL in August 2016 and commencement of U.S. sales in October 2016. Its pipeline included CINVANTI, an NDA-pending CINV treatment, and HTX-011, a Phase 2 post-operative pain candidate.
Financial Performance and Position
| Metric | Q1 2017 | Q1 2016 | Change |
|---|---|---|---|
| Net product sales | $3.6 million | $0 | New SUSTOL sales |
| Cost of product sales | $1.2 million | $0 | Includes $0.9 million inventory write-off |
| Gross profit and margin | $2.4 million; approximately 67% | Not applicable | First commercial period |
| Research and development | $33.4 million | $16.1 million | Up approximately 107% |
| General and administrative | $6.7 million | $5.4 million | Up approximately 26% |
| Sales and marketing | $11.6 million | $11.9 million | Down approximately 2% |
| Loss from operations | $49.3 million | $33.3 million | Loss increased |
| Net loss | $50.3 million | $33.4 million | Loss increased approximately 51% |
| Net loss per share | $1.00 | $0.92 | Loss per share increased |
| Cash used in operating activities | $50.6 million | $32.4 million | Use increased approximately 56% |
Operating loss was substantially larger than revenue, producing an operating loss margin of approximately 1,357% of reported sales. Research and development spending increased primarily because of HTX-011 clinical and manufacturing activities, CINVANTI development, SUSTOL-related costs and stock-based compensation.
At March 31, 2017, cash and cash equivalents were $83.5 million, short-term investments were $81.7 million, and total cash, cash equivalents and short-term investments were $165.2 million, compared with $51.1 million at December 31, 2016. Total assets were $189.6 million and stockholders’ equity was $102.2 million, compared with a deficit of $21.3 million at year-end 2016.
Debt included a $50.0 million secured promissory note bearing 8% interest and $6.1 million of principal under secured convertible notes, carried at $3.1 million net of discount. The company reported compliance with the convertible-note covenants. The promissory note is secured by a second-priority lien, while the convertible notes are secured by substantially all company assets.
Material Changes Versus the Prior Comparable Period
- SUSTOL generated $3.6 million of recognized net product sales; there was no comparable product revenue in Q1 2016.
- As of March 31, 2017, $5.2 million of SUSTOL shipments to distributors remained deferred because the company lacked sufficient historical data to estimate returns and other sales allowances. Revenue was recognized using a sell-through approach.
- Research and development expense more than doubled to $33.4 million, driven mainly by HTX-011 and CINVANTI development.
- Net cash used in operations increased to $50.6 million from $32.4 million.
- In January 2017, Heron sold 14.1 million shares in a public offering and received $163.7 million of net proceeds, materially strengthening liquidity but increasing share dilution.
- Interest expense increased to $1.0 million from $0.1 million, primarily because of the $50.0 million promissory note issued in August 2016.
- Stock-based compensation increased to $8.0 million from $5.4 million.
- The company recognized a $0.9 million one-time write-off of short-dated inventory in cost of product sales.
Guidance, Outlook, Risks and Unusual Items
Management did not provide formal numerical revenue or earnings guidance. Based on its current operating plan, management believed available cash, cash equivalents and short-term investments were sufficient to fund operations for at least one year from the filing date. The company nevertheless expected continued substantial losses and negative operating cash flow.
- CINVANTI’s NDA was pending FDA review with a Prescription Drug User Fee Act goal date of November 12, 2017.
- Following an anticipated End of Phase 2 meeting with the FDA, Heron expected to initiate HTX-011 Phase 3 studies in 2017 and file an NDA in 2018.
- The company expected to incur total realignment and severance-related expenses of $10.3 million. It had recognized $8.9 million through March 31, 2017, with approximately $1.4 million remaining; the final payment was expected in the second quarter of 2018.
- Revenue recognition, product returns, rebates, chargebacks and distributor fees were subject to significant estimates. Changes in those estimates could materially affect revenue and earnings.
- SUSTOL depended on physician and patient adoption, reimbursement, pricing, distribution, manufacturing execution and competition, including potential generic competition to ALOXI.
- Two specialty distributors each accounted for at least 10% of Q1 2017 net revenue, creating customer concentration risk.
- HTX-011 and CINVANTI remained subject to clinical, manufacturing and regulatory risks; positive Phase 2 results were not predictive of future success or approval.
- Additional financing might be required. Future equity financing could dilute shareholders, while secured debt covenants and liens could restrict financing and other corporate actions.
- The convertible notes could result in issuance of approximately 7.6 million shares if converted, creating material potential dilution.
- The company reported no legal proceedings, no defaults upon senior securities and no off-balance-sheet arrangements. Disclosure controls were judged effective at the reasonable-assurance level.
Important Facts for Investors to Verify
- Whether SUSTOL sell-through demand converts the $5.2 million deferred balance into recognized revenue and whether actual returns, rebates and chargebacks differ from estimates.
- The pace and economics of SUSTOL adoption, including reimbursement, gross margins, distributor concentration and competitive effects.
- FDA action on the CINVANTI NDA by the November 12, 2017 target date.
- HTX-011 Phase 3 initiation, clinical results, manufacturing readiness and the expected 2018 NDA filing.
- Cash burn relative to the $165.2 million liquidity balance and whether additional capital will be needed before profitability.
- Terms, covenants, collateral and potential dilution associated with the secured promissory note and convertible notes.
- The remaining realignment and severance obligations and the effect of the short-dated inventory write-off on reported margins.
- Potential generic competition, particularly the timing and impact of generic ALOXI, as well as competing CINV and post-operative pain products.